JP2023518044A - Nlrp3モジュレーター - Google Patents

Nlrp3モジュレーター Download PDF

Info

Publication number
JP2023518044A
JP2023518044A JP2022555714A JP2022555714A JP2023518044A JP 2023518044 A JP2023518044 A JP 2023518044A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2023518044 A JP2023518044 A JP 2023518044A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022555714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518044A5 (cg-RX-API-DMAC7.html
Inventor
モーハン,ラジュ
ナス,ジョン
ハリス,ジェイソン
ユアン,シェンドン
Original Assignee
ズーマゲン バイオサイエンシーズ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ズーマゲン バイオサイエンシーズ エルティーディー filed Critical ズーマゲン バイオサイエンシーズ エルティーディー
Publication of JP2023518044A publication Critical patent/JP2023518044A/ja
Publication of JP2023518044A5 publication Critical patent/JP2023518044A5/ja
Priority to JP2025033957A priority Critical patent/JP7892820B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Burglar Alarm Systems (AREA)
JP2022555714A 2020-03-16 2021-03-15 Nlrp3モジュレーター Ceased JP2023518044A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025033957A JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990363P 2020-03-16 2020-03-16
US62/990,363 2020-03-16
PCT/US2021/022397 WO2021188450A1 (en) 2020-03-16 2021-03-15 Nlrp3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025033957A Division JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Publications (2)

Publication Number Publication Date
JP2023518044A true JP2023518044A (ja) 2023-04-27
JP2023518044A5 JP2023518044A5 (cg-RX-API-DMAC7.html) 2024-03-18

Family

ID=77747550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555714A Ceased JP2023518044A (ja) 2020-03-16 2021-03-15 Nlrp3モジュレーター
JP2025033957A Active JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025033957A Active JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Country Status (16)

Country Link
US (4) US11603375B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121059A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023518044A (cg-RX-API-DMAC7.html)
KR (1) KR20220154165A (cg-RX-API-DMAC7.html)
CN (1) CN115605209B (cg-RX-API-DMAC7.html)
AR (1) AR121573A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021237477A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018480A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175729A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002531A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014499A2 (cg-RX-API-DMAC7.html)
IL (1) IL296488A (cg-RX-API-DMAC7.html)
MX (1) MX2022011576A (cg-RX-API-DMAC7.html)
PH (1) PH12022552447A1 (cg-RX-API-DMAC7.html)
TW (1) TWI901652B (cg-RX-API-DMAC7.html)
WO (1) WO2021188450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020312800B2 (en) 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
WO2021009567A1 (en) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
CA3175729A1 (en) 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
CN117247393A (zh) * 2022-06-17 2023-12-19 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
WO2025255532A1 (en) * 2024-06-07 2025-12-11 Zomagen Biosciences Ltd Combination therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034696A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
JP2019518071A (ja) * 2016-04-18 2019-06-27 アイエフエム トレ インコーポレイテッド Nlrp活性に関連する状態を処置するための化合物および組成物
US20190192478A1 (en) * 2016-01-25 2019-06-27 Galderma Research & Development Nlrp3 inhibitors for the treatment of inflammatory skin disorders
JP2020505381A (ja) * 2017-01-23 2020-02-20 ジェネンテック, インコーポレイテッド インターロイキン−1活性の阻害剤としての化学化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119705A1 (en) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
ES2668834T3 (es) * 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
CN107207431B (zh) * 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US11840543B2 (en) * 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
CN110914256A (zh) * 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
ES2927851T3 (es) 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US20200399242A1 (en) * 2018-03-02 2020-12-24 Inflazome Limited Novel compounds
MA53172A (fr) * 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
AU2020312800B2 (en) 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
WO2021009567A1 (en) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
CA3175729A1 (en) 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190192478A1 (en) * 2016-01-25 2019-06-27 Galderma Research & Development Nlrp3 inhibitors for the treatment of inflammatory skin disorders
JP2019518071A (ja) * 2016-04-18 2019-06-27 アイエフエム トレ インコーポレイテッド Nlrp活性に関連する状態を処置するための化合物および組成物
JP2020505381A (ja) * 2017-01-23 2020-02-20 ジェネンテック, インコーポレイテッド インターロイキン−1活性の阻害剤としての化学化合物
WO2019034696A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS

Also Published As

Publication number Publication date
US11603375B2 (en) 2023-03-14
CA3175729A1 (en) 2021-09-23
MX2022011576A (es) 2022-10-18
CN115605209A (zh) 2023-01-13
WO2021188450A1 (en) 2021-09-23
BR112022018480A2 (pt) 2022-11-29
JP7892820B2 (ja) 2026-07-21
US20210292336A1 (en) 2021-09-23
AR121573A1 (es) 2022-06-15
US20240101571A1 (en) 2024-03-28
US20260200935A1 (en) 2026-07-16
EP4121059A1 (en) 2023-01-25
PH12022552447A1 (en) 2024-01-03
TW202200584A (zh) 2022-01-01
AU2021237477A1 (en) 2022-10-13
US20230183258A1 (en) 2023-06-15
CL2022002531A1 (es) 2023-03-31
TWI901652B (zh) 2025-10-21
CN115605209B (zh) 2024-12-17
IL296488A (en) 2022-11-01
CO2022014499A2 (es) 2023-02-16
KR20220154165A (ko) 2022-11-21
EP4121059A4 (en) 2023-12-13
JP2025102771A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
JP7595642B2 (ja) Nlrp3モジュレーター
JP2024529839A (ja) Nlrp3モジュレーター
CN115605209B (zh) Nlrp3调节剂
JP7723652B2 (ja) 多発性硬化症(MS)の治療のためのNLPR3モジュレーターとしてのN-((1,2,3,5,6,7-ヘキサヒドロ-s-インダセン-4-イル)カルバモイル)-4,5,6,7-テトラヒドロベンゾフラン-2-スルホンアミド誘導体および関連化合物
AU2020218267A1 (en) TYK2 pseudokinase ligands
DE69813605T2 (de) Benzofuranderivate
EA049038B1 (ru) Модуляторы nlrp3
WO2025059069A1 (en) Nlrp3 modulators
EA051075B1 (ru) Модуляторы nlrp3
EA048687B1 (ru) ПРОИЗВОДНЫЕ N-((1,2,3,5,6,7-ГЕКСАГИДРО-s-ИНДАЦЕН-4-ИЛ)КАРБАМОИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗОФУРАН-2-СУЛЬФОНАМИДА И СВЯЗАННЫЕ СОЕДИНЕНИЯ В ВИДЕ МОДУЛЯТОРОВ NLPR3 ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221128

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250205

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250623